Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion type Assertion NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_head.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion description "[The primary study objective was to determine the safety of intraprostatic administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD)/herpes simplex virus thymidine kinase (HSV-1 TK) fusion gene concomitant with increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and conventional-dose three-dimensional conformal radiation therapy (3D-CRT) in patients with newly diagnosed, intermediate- to high-risk prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_provenance.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion evidence source_evidence_literature NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_provenance.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion SIO_000772 14612551 NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_provenance.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion wasDerivedFrom befree-20140225 NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_provenance.
- NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_assertion wasGeneratedBy ECO_0000203 NP507807.RA_A86W5lC73ahiqbzchjai_EtM28OjHO3VDwyiXFITZM130_provenance.